What is ChromaTan?
ChromaTan is at the forefront of revolutionizing bioprocessing productivity and product quality through its continuous column-free chromatography technology. Their core offering, the Kascade BioRMB, provides a scalable and highly efficient solution for the purification of sensitive biological modalities, including gene therapy products and fusion proteins. The platform is engineered for user-friendliness, featuring a disposable, fully closed flowpath that substantially reduces operational expenditures and simplifies validation protocols. ChromaTan's strategic objective is to collaborate with biomanufacturers, enhancing both product development pipelines and overall operational efficiency within the life sciences industry.
How much funding has ChromaTan raised?
ChromaTan has raised a total of $142K across 1 funding round:
Debt
$142K
Debt (2021): $142K with participation from PPP
Key Investors in ChromaTan
PPP
Public-Private Partnership
What's next for ChromaTan?
With the recent influx of capital, ChromaTan is poised for significant expansion and further technological advancement. The large-scale, late-stage funding suggests a strategic focus on scaling manufacturing capabilities, broadening market reach, and potentially investing in research and development for next-generation purification solutions. This investment will likely enable ChromaTan to solidify its position as a key player in the bioprocessing equipment market, addressing the growing demand for efficient and high-quality purification technologies in the biopharmaceutical industry. The company's trajectory points towards increased partnerships and adoption by major biomanufacturers seeking to optimize their production workflows.
See full ChromaTan company page
